Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | CFTR | P13569 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14288463 | 0.95 | TBXAS1 (0.64) | TBXAS1PDE4DCFTRSLC6A2SLC6A4 | |
| SCHEMBL23970158 | 0.89 | TBXAS1 (0.56) | TBXAS1PDE4DCFTRSLC6A2SLC6A4 | |
| SCHEMBL11737326 | 0.89 | CYP19A1 (0.55) | TBXAS1PDE4DCFTRSLC6A2SLC6A4 | |
| SCHEMBL659775 | 0.85 | CFTR (0.53) | TBXAS1PDE4DCFTRSLC6A2SLC6A4 | |
| SCHEMBL1293020 | 0.83 | SIGMAR1 (0.61) | SLC6A2SLC6A4SLC6A3SMN1; SMN2KCNH2 | |
| SCHEMBL21820673 | 0.82 | PDE4D (0.54) | TBXAS1PDE4DCFTRSLC6A2SLC6A4 | |
| SCHEMBL11528137 | 0.82 | L3MBTL1 (0.49) | TBXAS1PDE4DCFTRSLC6A2SLC6A4 | |
| SCHEMBL1944201 | 0.82 | CFTR (0.59) | TBXAS1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8775886 | 0.81 | TBXAS1 (0.68) | TBXAS1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6158955 | 0.81 | EPHX2 (0.51) | TBXAS1CFTRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| US-9856260-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2016-09-15 | — | — | US | disclosed |
| US-9375474-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| US-9375474-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | Alliance Discovery, Inc. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | Alliance Discovery, Inc. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8435993-B2 | Methods of inhibiting metastasis from cancer | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2012078633-A2 | METHODS OF INHIBITING METASTASIS FROM CANCER | PHILADELPHIA HEALTH AND EDUCATION CORPORATION, D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICENE (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | TBXAS1 2484/4885PDE4D 1840/4885CFTR 468/4885 |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | CX3CR1, CCL2, CCR5 | TBXAS1 2484/4885PDE4D 1840/4885CFTR 468/4885 |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | CX3CR1, CXCR3, CCR5 | TBXAS1 2988/4885PDE4D 1471/4885CFTR 553/4885 |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | TBXAS1 2484/4885PDE4D 1840/4885CFTR 468/4885 |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | TBXAS1 2484/4885PDE4D 1840/4885CFTR 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.